Monday, March 5, 2012

Wyeth Receives Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine

VACCINE REPORT

The US Food and Drug Administration (FDA) has granted Fast Track designation to Wyeth Pharmaceutical' (Collegeville, PA) investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking a pediatric indication for active immunization against invasive pneumococcal disease and otitis media caused by serotypes included in the vaccine.

The vaccine includes six new serotypes (1,3,5, 6A, 7F, and 19A) in addition to the seven serotypes (4, 6B, 9V, 14, 18C, 19F, and …

No comments:

Post a Comment